Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | -$0.46 | -$0.09 | -$0.21 |
Q2 2024 | 2 | -$0.31 | -$0.06 | -$0.15 |
Q3 2024 | 2 | -$0.03 | -$0.01 | -$0.02 |
Q4 2024 | 6 | -$0.14 | -$0.05 | -$0.09 |
Q1 2025 | 2 | $0.09 | $0.43 | $0.20 |
Q2 2025 | 1 | -$0.20 | -$0.04 | -$0.10 |
Q3 2025 | 1 | -$0.21 | -$0.04 | -$0.10 |
Q4 2025 | 1 | -$0.15 | -$0.03 | -$0.07 |
Q1 2026 | 1 | -$0.18 | -$0.04 | -$0.08 |
Q2 2026 | 1 | -$0.16 | -$0.03 | -$0.08 |
Q3 2026 | 1 | -$0.15 | -$0.03 | -$0.07 |
Q4 2026 | 1 | -$0.14 | -$0.03 | -$0.06 |
Sangamo Therapeutics, Inc. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.17 earnings per share for the quarter, missing analysts' consensus estimates of $-0.16 by $0.01. The company had revenue of 49.41 M for the quarter and had revenue of 176.23 M for the year. Sangamo Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.48 diluted earnings per share) and currently has a price-to-earnings ratio of -3.69. Sangamo Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | $0.05 | $20.92 M | $49.41 M | ||
08/06/2024 | Q2 2024 | -$0.16 | -$0.18 | -0.02 | $6.88 M | $356,000 |
05/09/2024 | Q1 2024 | -$0.22 | -$0.27 | -0.05 | $481,000 | |
03/13/2024 | Q4 2023 | -$0.25 | -$0.34 | -0.09 | $2.04 M | |
11/01/2023 | Q3 2023 | -$0.33 | -$0.59 | -0.26 | $9.36 M | $9.40 M |
08/08/2023 | Q2 2023 | -$0.35 | -$0.66 | -0.31 | $16.75 M | $6.84 M |
05/08/2023 | Q1 2023 | -$0.33 | $0.13 | 0.46 | $157.96 M | |
02/22/2023 | Q4 2022 | -$0.32 | $27.23 M | |||
11/03/2022 | Q3 2022 | -$0.35 | -$0.34 | 0.01 | $26.59 M | $26.46 M |
08/04/2022 | Q2 2022 | -$0.35 | -$0.29 | 0.06 | $24.63 M | $29.38 M |
05/05/2022 | Q1 2022 | -$0.32 | -$0.30 | 0.02 | $28.23 M | |
02/24/2022 | Q4 2021 | -$0.34 | -$0.26 | 0.08 | $27.99 M | |
11/04/2021 | Q3 2021 | -$0.34 | -$0.33 | 0.01 | $25.96 M | $28.56 M |
08/05/2021 | Q2 2021 | -$0.30 | -$0.33 | -0.03 | $26.53 M | $27.87 M |
05/04/2021 | Q1 2021 | -$0.29 | -$0.32 | -0.03 | $26.28 M | |
02/24/2021 | Q4 2020 | -$0.18 | -$0.29 | -0.11 | $25.80 M | |
11/04/2020 | Q3 2020 | -$0.24 | -$0.01 | 0.23 | $26.55 M | $57.76 M |
08/05/2020 | Q2 2020 | $0.41 | -$0.26 | -0.67 | $102.71 M | $21.55 M |
05/11/2020 | Q1 2020 | -$0.23 | -$0.37 | -0.14 | $13.08 M | |
02/28/2020 | Q4 2019 | -$0.31 | $0.04 | 0.35 | $54.85 M |
Sangamo Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates.
The conference call for Sangamo Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Sangamo Therapeutics, Inc.'s latest earnings report can be read online.
Sangamo Therapeutics, Inc. (:SGMO) has a recorded annual revenue of $176.23 M.
Sangamo Therapeutics, Inc. (:SGMO) has a recorded net income of $176.23 M. Sangamo Therapeutics, Inc. has generated $-1.48 earnings per share over the last four quarters.
Sangamo Therapeutics, Inc. (:SGMO) has a price-to-earnings ratio of -3.69 and price/earnings-to-growth ratio is -0.08.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED